The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Collaboration aims to align hospital staff learning with NABH 6th Edition standards, patient safety, and measurable quality outcomes
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Paves the way for next-gen ultra-precise gas sensing
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
